Maintaining Bone Strength in Men With Prostate Cancer
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if giving zoledronic acid three times a year is as
effective as five times a year, in increasing bone strength in men with prostate cancer. All
participants will receive the active drug but half will receive drug every 6 months and the
other half will receive drug every 3 months. Both patient and doctor will know which
treatment a patient is receiving.
After 1 year of treatment bone strength will be measured with scans and compared to the
strength at the start of the study. All participants will stop receiving the drug after 1
year and will be seen back in the clinic, annually for another 2 years for follow-up.